Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Abstract

IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials. OBJECTIVES To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival. DESIGN, SETTING, AND PARTICIPANTS From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through 2 and tested their tumors for 10 drivers. Information was collected on patients, therapies, and survival. INTERVENTIONS Tumors were tested for 10 oncogenic drivers, and results were used to select matched targeted therapies. MAIN OUTCOMES AND MEASURES Determination of the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival. RESULTS From 2009 through 2012, tumors from 1007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64%). Among these 733 tumors, 182 tumors (25%) had the KRAS driver; sensitizing EGFR, 122 (17%); ALK rearrangements, 57 (8%); other EGFR, 29 (4%); 2 or more genes, 24 (3%); ERBB2 (formerly HER2), 19 (3%); BRAF, 16 (2%); PIK3CA, 6 (<1%); MET amplification, 5 (<1%); NRAS, 5 (<1%); MEK1, 1 (<1%); AKT1, 0. Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%). The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy (propensity score–adjusted hazard ratio, 0.69 [95% CI, 0.53-0.9], P = .006). CONCLUSIONS AND RELEVANCE Actionable drivers were detected in 64% of lung adenocarcinomas. Multiplexed testing aided physicians in selecting therapies. Although individuals with drivers receiving a matched targeted agent lived longer, randomized trials are required to determine if targeting therapy based on oncogenic drivers improves survival.

Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging

“…The 2015 World Health Organization classification of lung tumors recognizes three types of squamous cell carcinoma: keratinizing, nonkeratinizing, and basaloid. 14 We used this simple subtyping scheme and essentially demonstrated a very similar disagreement with Martini-Melamed criteria as for adenocarcinoma. In our opinion, this is an encouraging observation indicating a potential application of the WHO subtyping of squamous cell carcinoma.…”

Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study

“…The panel of investigated genes was quite comparable to that investigated by the Lung Cancer Mutation Consortium [13] and in a French National Study [14]. The incidence of mutations in these two large studies and in our case-series cannot be compared for several reasons including our limited sample size and the influence of selection factors (i.e.…”

“…clinical enrichment criteria mainly for EGFR mutation and ALK translocation) that in our centre drove the clinical decision of performing a second biopsy. This explains why 44% of the cases harboured "druggable" molecular alterations (actEGFR and ALK), whereas 30% of cases showed mutations in genes usually associated to acquired resistance to targeted therapies (namely, MET, KRAS, EGFR_p.T790M and PIK3CA [13]). These data support the hypothesis of a primary mechanism of resistance, such as EGFR p.T790M mutation and MET gene copy number alteration, in tumour specimens of patients with no prior exposure to EGFR TKI [15].…”

NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies

“…58 Although the exploitation of activating EGFR mutations as the major determinants of responsiveness to the EGFR TKIs erlotinib, afatinib, or gefitinib largely occurred retrospectively after the initial development of these drugs, newer examples of personalized therapy in lung cancer have occurred prospectively 59–61 . Perhaps the best example is represented by activating rearrangements of the anaplastic lymphoma kinase ( ALK ) gene, which have been found in 4 to 7% of NSCLC patients.…”